It exerts its antitumor activity by inhibiting multiple receptor tyrosine kinases, including KIT, PDGFRA, PDGFRB, VEGFRs, RET and FLT3, thereby targeting both tumor cell proliferation and angiogenesis (Figure 2 and Figure 3) [32,33,34]. This evidence concerns the gene PDGFRA and neoplasm.